Home
/
Conditions
/ Mast Cell Activation Syndrome
Inflammation & Immune
Schedule a Consultation
Mast Cell Activation Syndrome
Mast cell activation syndrome (MCAS) is an increasingly recognized pattern of immune hyperreactivity in which mast cells trigger inappropriately to a wide range of environmental stimuli, releasing inflammatory mediators that produce multi-system symptoms. It frequently co-exists with autoimmune conditions, SIBO, histamine intolerance, and hypermobility spectrum disorders, and is consistently under-diagnosed in functional medicine practice.
Inflammation & ImmuneImmune HyperreactivityStabilizable
Multi-Systemmast cell mediators affect every organ system simultaneously
Triggersmast cells in MCAS respond to stimuli that would not activate normal mast cells
Stabilizablewith targeted mast cell stabilization, trigger reduction, and anti-inflammatory support
← Back to Conditions
Category: Inflammation and Immune | Also addressed: MCAS, Mast Cell Activation Syndrome, Mast Cell Disease
What Is Mast Cell Activation?
Mast cell activation syndrome (MCAS) is a condition in which mast cells degrade inappropriately in response to triggers that would not activate mast cells in a healthy immune system. Each degranulation event releases histamine, tryptase, prostaglandins, leukotrienes, and cytokines that drive the multi-system, episodic, and often unpredictable symptom pattern that makes MCAS one of the most challenging presentations in functional medicine.
MCAS exists on a spectrum from primary clonal mast cell disease such as systemic mastocytosis, to secondary reactive mast cell hyperreactivity from identifiable upstream triggers including gut dysbiosis, chronic infections, and hormonal imbalance, to idiopathic. The vast majority of functional medicine MCAS patients have secondary or idiopathic MCAS, meaning the mast cells are inherently normal but are being chronically primed to overreact by identifiable and modifiable upstream drivers.
Key principle: MCAS is a total burden condition. Mast cells have a threshold for degranulation, and that threshold is lowered by the cumulative burden of triggers including gut dysbiosis, dietary histamine, psychological stress, hormonal fluctuations, and environmental exposures. Reducing the total trigger burden from every identifiable source, even without eliminating any single trigger completely, reliably reduces symptom frequency and severity.
Why It Matters
MCAS is vastly underdiagnosed and frequently misattributed to anxiety, multiple food allergies, IBS, or somatization. The multi-system, trigger-dependent, and episodic nature of symptoms produces a clinical pattern that does not fit conventional diagnostic categories, and years of evaluation without identification of the mast cell mechanism are common.
Why Identification Matters
- Post-viral MCAS: COVID-19 and other viral infections prime mast cells for persistent hyperreactivity; the multi-system sensitivity of Long COVID frequently has a primary MCAS mechanism that requires specific evaluation
- Histamine intolerance compounding: MCAS increases the endogenous histamine load that DAO enzyme must degrade; the two conditions co-exist in a large proportion of patients and require simultaneous treatment of both mechanisms
- Untreated MCAS sustains chronic inflammation: continuous mediator release maintains the inflammatory tissue environment across all systems mast cells are distributed in, driving persistent fatigue, gut dysfunction, and neurological symptoms
- Anaphylaxis risk in unidentified MCAS: patients without a diagnosis may not carry epinephrine; identification changes the safety picture immediately and allows appropriate emergency preparedness
Organ Systems Affected
- Skin: flushing, urticaria, angioedema, dermatographia, and pruritus from dermal mast cell degranulation
- Gastrointestinal: abdominal cramping, bloating, nausea, diarrhea, and reflux from intestinal mast cell activation
- Neurological: brain fog, anxiety, palpitations, and orthostatic intolerance from mast cell mediator effects on the autonomic nervous system
- Respiratory and mucosal: nasal congestion, postnasal drip, chronic sinusitis, and wheezing from upper respiratory mast cell activation
Common Symptoms
MCAS symptoms are episodic and multi-system, which distinguishes them from most single-organ diagnoses. Triggers can include foods, fragrances, temperature changes, stress, exercise, alcohol, and medications in combinations that do not fit allergy patterns and are frequently labeled psychosomatic before MCAS is correctly identified.
Skin and Cardiovascular
- Flushing, especially facial, after foods, alcohol, or temperature change
- Urticaria and hives from dermal histamine receptor activation
- Angioedema, episodic swelling of face, lips, or throat
- Palpitations from histamine's positive chronotropic cardiac effect
- Orthostatic hypotension from histamine-mediated vasodilation
Gastrointestinal
- Abdominal cramping and bloating often after eating, without consistent food trigger
- Diarrhea, sometimes alternating with constipation
- Nausea and reflux from gastric mast cell activation and motility effects
- IBS symptom worsening with high-histamine or heat-exposed foods
- Difficulty maintaining weight from digestive reactivity and food restriction
Neurological and Respiratory
- Brain fog and cognitive impairment during and after degranulation episodes
- Anxiety and panic symptoms from mast cell mediator release in the CNS
- Nasal congestion and chronic sinusitis from mucosal mast cell activation
- Headache and migraine from histamine-driven vasodilation
- Exercise intolerance when physical exertion triggers degranulation
Root Causes: A Functional Medicine Perspective
Identifying the specific drivers priming mast cell hyperreactivity and reducing the total burden from each simultaneously produces the most durable improvement. Secondary MCAS is not a permanent condition when the triggers are identified and removed.
Gut Dysbiosis as the Primary Driver
Intestinal mast cells represent the largest concentration of mast cells in the body and are in direct contact with the gut microbiome. Gut dysbiosis, particularly SIBO, Candida overgrowth, and elevated opportunistic pathogens, chronically stimulates intestinal mast cells through LPS and other microbial antigens, priming them for systemic hyperreactivity. This is why MCAS symptoms so frequently include a prominent gut component and why GI-MAP-directed gut restoration is one of the most effective MCAS interventions available. Treating the gut removes the primary mast cell priming signal affecting the entire system.
Hormonal Drivers: Estrogen and the Mast Cell Connection
Estrogen directly upregulates mast cell histamine release and sensitization through estrogen receptors expressed on mast cell membranes. This explains the consistent clinical pattern of MCAS symptom worsening premenstrually, during perimenopause, and with estrogen-containing medications. Progesterone, by contrast, directly stabilizes mast cells. Women with estrogen dominance or perimenopausal estrogen fluctuations carry a significantly higher MCAS burden, and hormonal evaluation alongside mast cell-specific treatment is necessary for full resolution in this population.
Chronic Infections and Post-Viral Priming
EBV reactivation, Lyme co-infections including Bartonella specifically, COVID-19, and other reactivating infections prime mast cells for persistent hyperreactivity through TLR activation. The mast cell remains sensitized long after the acute infection resolves, explaining the post-viral MCAS onset pattern seen so consistently in Long COVID. Testing and treating reactivated EBV or chronic bacterial co-infections in MCAS patients with a clear post-infectious onset significantly improves outcomes that mast cell stabilization alone cannot achieve.
Environmental Triggers: Mold and Chemical Exposure
Mycotoxin exposure from water-damaged buildings is one of the most severe and most overlooked MCAS triggers, producing whole-body mast cell hyperreactivity that does not improve with any other intervention until the mold exposure is identified and removed. Chemical sensitivities to fragrances, pesticide residues, and volatile organic compounds activate sensitized mast cells at exposures that healthy immune systems handle without response. Occupational and residential exposure history is a mandatory component of complete MCAS evaluation.
Conventional vs Functional Medicine Approach
Conventional allergy and immunology manages MCAS primarily with antihistamines, mast cell stabilizers such as cromolyn sodium and ketotifen, and trigger avoidance. These are appropriate first-line interventions that reduce symptom burden. What they do not address is why the mast cells are hyperreactive in the first place. The gut dysbiosis, hormonal drivers, chronic infections, and environmental exposures priming mast cells for inappropriate degranulation require a root-cause evaluation that is not currently part of standard MCAS protocols.
| Domain | Conventional Medicine | Functional Medicine |
|---|---|---|
| Diagnosis | Elevated serum tryptase during episode; often not captured; clinical diagnosis by exclusion | 24-hour urinary mast cell mediators (N-methylhistamine, PGD2 metabolite) plus GI-MAP, hormonal evaluation, and environmental and infectious trigger assessment |
| Root cause | Not systematically investigated; MCAS treated as idiopathic | Gut dysbiosis, estrogen excess, post-viral priming, mycotoxin exposure, and chemical triggers identified and addressed |
| Treatment | H1/H2 antihistamines, cromolyn, ketotifen, trigger avoidance | Mast cell stabilization plus gut restoration, hormonal optimization, infectious trigger treatment, and environmental burden reduction |
| Diet | Low-histamine diet recommended, rarely individualized or time-limited | Low-histamine as a temporary therapeutic strategy during stabilization; histamine-producing probiotics specifically contraindicated; systematic reintroduction follows as burden reduces |
| Outcome expectation | Chronic management; MCAS considered a permanent condition | Meaningful reduction and often resolution when secondary triggers are identified and removed |
Key Labs to Evaluate
A complete evaluation requires markers that characterize both the condition and the upstream drivers producing it.
Mast Cell Mediator Markers
Serum TryptaseElevated above 11.4 ng/mL, or above 20% over baseline during symptoms, is the primary MCAS biomarker.
→Urinary N-Methylhistamine24-hour urine histamine metabolite; more stable than serum histamine for total mast cell burden assessment.
→Urinary PGD2 MetaboliteProstaglandin D2 is a primary mast cell mediator; elevated urine metabolite confirms active mast cell degranulation.
→Upstream Driver Assessment
GI-MAP Stool AnalysisIdentifies the gut dysbiosis patterns sustaining intestinal mast cell priming.
→Total and Specific IgEDistinguishes true IgE-mediated allergy from non-IgE mast cell degranulation.
→DUTCH Complete TestEvaluates estrogen metabolites and cortisol; estrogen excess is a direct mast cell sensitizer.
→How to Interpret These Labs Together
A single normal tryptase does not exclude MCAS. Tryptase spikes during active degranulation and normalizes within hours. Serial measurements, or 24-hour urinary mediator collections over a symptomatic period, are far more diagnostically sensitive than a single serum tryptase drawn at a scheduled clinic visit.
The combination of elevated urinary N-methylhistamine plus elevated urinary PGD2 metabolite with episodic multi-system symptoms is strongly diagnostic for MCAS regardless of whether any single measurement exceeds reference ranges at the time of collection.
| Pattern | Clinical Implication |
|---|---|
| Normal tryptase in a symptomatic patient | Does not exclude MCAS. 24-hour urinary mediators and clinical pattern are more reliable. Most MCAS patients have episodically elevated, not chronically elevated, tryptase. |
| Elevated urinary N-methylhistamine with gut dysbiosis on GI-MAP | Gut-driven MCAS pattern. Intestinal mast cell priming from dysbiosis is the primary mechanism. GI-MAP-directed gut restoration is the highest-leverage intervention. |
| MCAS symptoms worsening premenstrually or during perimenopause | Estrogen-driven mast cell sensitization pattern. DUTCH testing for estrogen metabolites and progesterone is required alongside mast cell stabilization. |
| MCAS onset following viral illness or COVID-19 | Post-viral mast cell priming pattern. EBV antibody panel and immune evaluation are appropriate. LDN and viral immune support alongside standard mast cell stabilization. |
| MCAS not responding to H1/H2 antihistamines and cromolyn | Strongly suggests an unidentified environmental trigger such as mycotoxin or chemical exposure, or a persistent infectious driver. Environmental history and mycotoxin testing are warranted before declaring treatment failure. |
Common Patterns Seen in Patients
- Multi-system reactivity to diverse and seemingly unrelated triggers: the patient who reacts to foods, fragrances, temperature, stress, exercise, and medications in combinations that do not fit allergy patterns and have been labeled psychosomatic across multiple specialty consultations; MCAS is the unifying mechanism that makes sense of the entire clinical picture
- Post-COVID onset with new multi-system sensitivity: previously tolerant of foods, fragrances, and environmental exposures who developed new and broad reactivity following COVID-19; the high probability of virus-primed MCAS requires mast cell evaluation as the primary diagnostic framework before other explanations are pursued
- Worsening premenstrually or during perimenopause: the cycle-dependent MCAS pattern driven by estrogen-mast cell sensitization requires hormonal evaluation alongside mast cell treatment; managing estrogen dominance through progesterone repletion and gut beta-glucuronidase normalization is as important as any mast cell stabilizer in this population
- Residence or work in a water-damaged building with whole-body reactivity: mycotoxin-driven MCAS is the most severe presentation and the one most consistently misdiagnosed or declared treatment-resistant; no mast cell stabilization protocol produces durable improvement while active mycotoxin exposure continues and the exposure source has not been removed
Treatment and Optimization Strategy
Mast Cell Stabilization as the Foundation
Mast cell stabilization reduces symptom burden and creates the therapeutic window needed to address root causes without triggering severe reactions to the interventions themselves. Quercetin (500 to 1,000mg three times daily) is the most potent natural mast cell stabilizer, directly inhibiting degranulation through calcium channel modulation. Vitamin C (1g three times daily) depletes histamine and supports DAO enzyme activity. Luteolin (100mg twice daily) provides additional mast cell stabilization with anti-neuroinflammatory properties particularly relevant for MCAS-associated brain fog. These natural stabilizers are used alongside low-dose ketotifen or cromolyn sodium for the first 2 to 4 months while root-cause treatment reduces the upstream mast cell priming burden.
Root Cause Treatment
- Gut restoration as the primary intervention: GI-MAP-directed SIBO treatment followed by Bifidobacterium-dominant probiotic reseeding removes the primary intestinal mast cell priming signal; L-glutamine and zinc carnosine for mucosal repair reduces intestinal permeability allowing LPS and food antigens to reach submucosal mast cells; histamine-producing Lactobacillus species are specifically contraindicated during active MCAS treatment
- Hormonal management: DUTCH complete testing evaluates estrogen metabolites and progesterone; bioidentical progesterone repletion (100 to 200mg nightly) directly stabilizes mast cells through progesterone receptor signaling; reducing estrogen burden through gut beta-glucuronidase normalization and DIM (200mg daily) reduces the primary hormonal mast cell sensitization driver
- Post-viral and infectious trigger treatment: EBV VCA IgG and EA IgG for reactivated latent EBV; low-dose naltrexone (1.5 to 4.5mg nightly) modulates TLR-4 and supports NK cell function for viral immune surveillance; Bartonella and Lyme co-infection evaluation when post-infectious onset is clearly established
- Mycotoxin remediation: urine mycotoxin testing in patients with water-damaged building exposure history; mold exposure removal is non-negotiable before any other MCAS treatment can produce durable results; binders including cholestyramine and activated charcoal are used after exposure removal is confirmed
Dietary and Environmental Management
- Low-histamine diet during active treatment: eliminating aged cheeses, fermented foods, alcohol, canned fish, vinegar, and leftover cooked foods reduces the dietary histamine load competing with DAO capacity during active stabilization; this is a 4- to 8-week therapeutic diet, not a permanent restriction; systematic food reintroduction follows as mast cell burden reduces
- DAO enzyme and cofactor support: supplemental DAO enzyme taken before high-histamine meals provides the degradation capacity that impaired gut production cannot; copper (2mg daily) is the DAO cofactor most commonly deficient; vitamin B6 as pyridoxal-5-phosphate supports HNMT-mediated intracellular histamine methylation
- Omega-3 fatty acids (3 to 4g EPA and DHA daily): shift the eicosanoid balance from pro-inflammatory mast cell mediators toward anti-inflammatory and pro-resolving lipid mediators; reduce the inflammatory amplitude of each degranulation event; omega-3 index target is 8 to 12% of erythrocyte fatty acid composition
- Fragrance and chemical exposure reduction: unscented personal care products, fragrance-free cleaning products, and HEPA air filtration reduce the ongoing chemical trigger burden activating sensitized mast cells; this is a significant quality-of-life intervention that reduces the frequency and severity of reactive episodes between other treatments
What Most Doctors Miss
- MCAS is labeled as anxiety or psychosomatic: the episodic, multi-system, trigger-dependent pattern with normal standard labs produces a presentation that does not fit conventional diagnostic categories and is routinely attributed to psychological causes through multiple specialty consultations before the mast cell mechanism is identified
- Gut dysbiosis as the primary MCAS driver is not evaluated: the largest concentration of mast cells in the body sits in the gut wall in direct contact with the microbiome, yet gastrointestinal evaluation is not included in standard MCAS workup in allergy or immunology practice
- Mold and mycotoxin exposure is not investigated: mycotoxin-driven MCAS is the most severe and most treatment-resistant presentation; it does not improve until exposure is removed; yet most MCAS protocols do not include environmental history or mycotoxin assessment as part of the initial evaluation
- Histamine-producing probiotics are prescribed: standard probiotic recommendations including Lactobacillus casei and L. reuteri significantly worsen histamine intolerance and MCAS by increasing the endogenous histamine burden; this is established biochemistry that is not yet communicated in mainstream prescribing guidance
- The hormonal MCAS connection is not evaluated: cycle-dependent worsening is noted in the history but estrogen as a direct mast cell sensitizer is not assessed or treated, leaving the most actionable hormonal driver of MCAS unaddressed in a large proportion of female patients
When to Seek Medical Care
Seek emergency care immediately for anaphylaxis: throat swelling, difficulty breathing, severe hypotension, or loss of consciousness following any trigger exposure. These require epinephrine and emergency management regardless of MCAS diagnostic status. Any patient with recurrent near-anaphylaxis reactions should carry an epinephrine auto-injector and have a documented anaphylaxis action plan regardless of concurrent MCAS treatment progress.
For the chronic multi-system MCAS pattern without anaphylaxis risk, functional medicine evaluation of gut, hormonal, and environmental drivers alongside conventional mast cell stabilization provides the most comprehensive management available. Allergy and immunology evaluation is appropriate concurrently to confirm the diagnosis and manage immediate hypersensitivity risk assessment.
Recommended Testing
Identifying the root cause of this condition requires going beyond standard labs. The following markers provide the most clinically useful insights.
Foundational Labs
- Serum Tryptase
- Urinary N-Methylhistamine
Advanced Assessment
- Urinary Prostaglandin D2 Metabolite
- GI-MAP Stool Analysis
- IgE Panel
Not sure which testing applies to you?
Explore All Testing Options →Frequently Asked Questions
How is MCAS formally diagnosed?
Formal MCAS diagnosis requires three criteria: episodic symptoms consistent with mast cell mediator release across two or more organ systems; demonstration of elevated mast cell mediators such as serum tryptase above 20% over baseline during symptoms, or elevated 24-hour urinary N-methylhistamine, PGD2 metabolite, or leukotriene E4; and response to mast cell-targeted treatment. Many patients with a clear clinical MCAS picture have normal single tryptase measurements because testing is not performed during active degranulation. Clinical diagnosis supported by 24-hour urine mediator panels and treatment response is often more useful than waiting for a single elevated tryptase at a scheduled visit.
Is MCAS a permanent condition?
MCAS secondary to identifiable and treatable triggers is not permanent. Gut dysbiosis, hormonal imbalance, mold exposure, and post-viral priming are all modifiable. Most patients with clearly identified root causes achieve meaningful reduction in symptom burden and trigger reactivity within 3 to 6 months of systematic treatment. Idiopathic MCAS requires longer-term mast cell stabilization management, though quercetin, ketotifen, and dietary management provide substantial ongoing symptom control. The prognosis is meaningfully better when root causes are identified than when MCAS is treated as purely idiopathic.
Why do standard probiotics worsen MCAS?
Many commonly used Lactobacillus species including L. casei and L. reuteri are significant histamine producers that worsen histamine intolerance and MCAS by increasing the endogenous histamine burden that DAO enzyme must degrade. This is established biochemistry that is not yet reflected in mainstream probiotic prescribing guidance. Bifidobacterium-dominant formulations and soil-based organisms are the appropriate probiotic choices during MCAS treatment. This single prescribing change eliminates a common cause of MCAS worsening during otherwise well-intentioned gut treatment protocols.
What is the connection between MCAS and POTS?
Postural orthostatic tachycardia syndrome (POTS) and MCAS co-occur at a rate far above chance, particularly in the hypermobile Ehlers-Danlos syndrome population. The mechanism involves mast cell mediator release, particularly histamine and prostaglandins, producing vasodilation and volume dysregulation that triggers the orthostatic tachycardia of POTS. Additionally, mast cells in autonomic nervous system ganglia may directly impair autonomic regulation. Treating the MCAS component through mast cell stabilization and gut restoration frequently improves POTS symptoms, and the two conditions are most effectively managed as parts of the same mast cell-autonomic complex rather than as independent diagnoses.
How The Lamkin Clinic Approaches Mast Cell Activation
Clinical Perspective
MCAS is one of the conditions where getting the mechanism right completely changes what you do for the patient. If someone has MCAS driven by gut dysbiosis and estrogen dominance, prescribing more antihistamines manages symptoms temporarily but the mast cells are still being primed every day by the dysbiosis and the estrogen. We need to fix the gut first, address the hormonal driver, and then the mast cell burden starts coming down from the inside rather than being suppressed from the outside. The patients who do best are the ones where we can clearly identify the upstream triggers and remove them. A mycotoxin-positive patient who remediates their home, a perimenopausal patient who restores progesterone, a post-COVID patient whose gut is rebuilt and whose viral immune burden is reduced: these are the patients who stop needing the symptom management because the underlying priming has been addressed.
Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma
Related Conditions
Histamine IntoleranceMCAS increases endogenous histamine production; the two conditions compound each other and require parallel treatment
→Autoimmune ActivationMast cell hyperreactivity and autoimmune activation share upstream gut and immune dysregulation drivers
→Gut DysbiosisThe primary location and most impactful driver of mast cell priming in most functional medicine MCAS patients
→Long COVIDCOVID-19 primes persistent mast cell hyperreactivity; MCAS is a major contributor to Long COVID multi-system sensitivity
→Estrogen DominanceEstrogen directly sensitizes mast cells; cycle-dependent MCAS worsening reflects this well-established connection
→Related Symptoms
FatigueChronic mast cell mediator release sustains the systemic inflammatory burden producing severe MCAS fatigue
→Brain FogNeuro-mast cell activation and histamine CNS effects produce the cognitive impairment characteristic of MCAS
→AnxietyMast cell mediator release produces the adrenergic arousal and limbic sensitization driving MCAS-associated anxiety
→Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.
Mast cell activation has identifiable root causes that determine the treatment.
The Lamkin Clinic evaluates MCAS with mast cell mediator testing, comprehensive gut assessment, hormonal evaluation, and environmental trigger identification. Schedule a consultation for a complete mast cell burden assessment.
Schedule a ConsultationMedical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.